Table 2.
Characteristics of the Study Patients in the Validation Cohort (n = 53)
| Characteristic | |
|---|---|
| Patients in study, n | 53 |
| Age at surgery, yrs. (SD) | 66 (9.3) |
| BMI, mean (SD) | 26.8 (6.2) |
| Median follow-up, months (range) | 31 (2–50) |
| Ca 125 level (kU/L) before treatment, median (range) | 523 (30–4728) |
| FIGO* Stage, n (%) | |
| Stage 1 | 2 (3,7%) |
| Stage 2 | 3 (5,6%) |
| Stage 3 | 34 (64,3%) |
| Stage 4 | 14 (26,4%) |
| Histology, n (%) | |
| Serous | 46 (86,8) |
| Endometroid | 4 (7,6%) |
| Papillar | 2 (3,7%) |
| Mucinous | 0 (0%) |
| Carcinosarcoma | 0 (0%) |
| Transitional cell | 1 (1,9%) |
| Grade†, n (%) | |
| Grade 1 and 2 | 10 (18%) |
| Grade 3 | 43 (82%) |
| Sensitivity to platinum therapy‡, n (%) | |
| Sensitive | 25 (47,2%) |
| Resistant | 15 (28,3%) |
| Partial sensitive | 13 (24,5%) |
| Neoadjuvant therapy, n (%) | 19 (36%) |
| Recurrence | 36 (68%) |
| Death | 22 (42%) |
*
FIGO = International Federation of Gynecology.
†
Grade – Grade 3 represents high grade tumors, Grade 1 and 2 low grade tumors.
‡
Sensitive: Recurrence >12 months after completion of platinum-based 1st line therapy; Resistant: Recurrence ≤6 months after completion of platinum-based 1st line therapy; Partially sensitive: Recurrence 6–12 months after completion of platinum-based 1st line therapy.